We observed similar BIM induction in sensitive ovarian cancer lines and in some cell lines that are not sensitive (Fig. 5b), ruling out differential BIM induction as the sole explanation for differences in paclitaxel sensitivity. This evidence concerns the gene BCL2L11 and ovarian cancer.